Cell cycle regulation by protein phosphatase 2A
蛋白磷酸酶 2A 的细胞周期调节
基本信息
- 批准号:8019096
- 负责人:
- 金额:$ 30.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-01-01 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAtherosclerosisBackBinding SitesCalciumCalcium BindingCalcium SignalingCell CycleCell Cycle ProteinsCell Cycle RegulationCell ProliferationCell divisionCellsChromatinComplexDNA Replication FactorDNA biosynthesisEnsureG1/S TransitionGene ExpressionGoalsMalignant NeoplasmsMammalian CellMediatingMolecularPathway interactionsPhosphoric Monoester HydrolasesPhosphorylationPre-Replication ComplexProtein DephosphorylationProtein KinaseProtein phosphataseProteinsRNA InterferenceRegulationReplication InitiationResistanceRetinoblastoma ProteinRoleS PhaseSignal PathwaySignal TransductionSpecificityStagingStructureTestingbasedimernovelpublic health relevanceresearch study
项目摘要
DESCRIPTION (provided by applicant): Inappropriate cell proliferation occurs in many pathological settings including cancer and atherosclerosis. The mammalian cell cycle is regulated by a network of signaling pathways that ensure cell division occurs with high fidelity and only under appropriate conditions. Many of these pathways converge on cell cycle check points that control passage from one stage to the next. Check points control the transition of cells from a quiescent state back into the cell cycle and the transition from G1 into S phase. Two proteins required for these transitions are the retinoblastoma protein, which controls the expression of genes required for G1 progression and the cell division cycle 6 proteins (Cdc6), which is required for initiating DNA replication at the G1/S transition. The level and activities of these proteins are regulated by the concerted actions of cell cycle regulated protein kinases and protein phosphatases. Recent evidence has shown that a calcium-regulated subunit of protein phosphatase 2A (PP2A) is involved in dephosphorylation of both of these proteins. This subunit (PR70) directly interacts with the retinoblastoma protein and Cdc6, and induces their dephosphorylation by targeting the catalytic components of PP2A to these substrates. The regulation of the PR70-containing form of PP2A by calcium has led to proposal of a novel signaling mechanism that allows cross-talk between agents that modify calcium signaling and agents that induce cell proliferation. The goals of this proposal are to test the hypothesis that the PR70 subunit of PP2A mediates calcium regulation of G1 progression by controlling the dephosphorylation of the retinoblastoma protein and Cdc6.
PUBLIC HEALTH RELEVANCE: Inappropriate cell proliferation occurs in many pathological settings including cancer and atherosclerosis. The mammalian cell cycle is regulated by a network of signaling pathways that ensure cell division occurs with high fidelity and only under appropriate conditions. Recent evidence has shown that a calcium-regulated subunit of a cellular protein phosphatase (PP2A) is involved in dephosphorylation of proteins that are critical for regulating the cell cycle. The goals of this proposal are to test the hypothesis that PP2A mediates calcium-dependent regulation of the cell cycle through actions on these proteins.
描述(由申请人提供):不适当的细胞增殖发生在许多病理情况下,包括癌症和动脉粥样硬化。哺乳动物细胞周期受到信号通路网络的调节,确保细胞分裂仅在适当的条件下以高保真度发生。许多这些途径汇聚在控制从一个阶段到下一阶段的通道的细胞周期检查点上。检查点控制细胞从静止状态转变回细胞周期以及从G1期转变为S期。这些转变所需的两种蛋白质是视网膜母细胞瘤蛋白,它控制 G1 进展所需基因的表达;以及细胞分裂周期 6 蛋白 (Cdc6),它是在 G1/S 转变时启动 DNA 复制所必需的。这些蛋白质的水平和活性受到细胞周期调节蛋白激酶和蛋白磷酸酶的协同作用的调节。最近的证据表明,蛋白磷酸酶 2A (PP2A) 的钙调节亚基参与这两种蛋白的去磷酸化。该亚基 (PR70) 直接与视网膜母细胞瘤蛋白和 Cdc6 相互作用,并通过将 PP2A 的催化成分靶向这些底物来诱导其去磷酸化。钙对含有 PR70 形式的 PP2A 的调节提出了一种新的信号传导机制,该机制允许修饰钙信号传导的药物与诱导细胞增殖的药物之间进行串扰。该提案的目的是检验以下假设:PP2A 的 PR70 亚基通过控制视网膜母细胞瘤蛋白和 Cdc6 的去磷酸化来介导 G1 进展的钙调节。
公共卫生相关性:不适当的细胞增殖发生在许多病理环境中,包括癌症和动脉粥样硬化。哺乳动物细胞周期受到信号通路网络的调节,确保细胞分裂仅在适当的条件下以高保真度发生。最近的证据表明,细胞蛋白磷酸酶 (PP2A) 的钙调节亚基参与对调节细胞周期至关重要的蛋白质的去磷酸化。该提案的目的是检验以下假设:PP2A 通过作用于这些蛋白质来介导细胞周期的钙依赖性调节。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc C. MUMBY其他文献
Marc C. MUMBY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc C. MUMBY', 18)}}的其他基金
Cell cycle regulation by protein phosphatase 2A
蛋白磷酸酶 2A 的细胞周期调节
- 批准号:
7749048 - 财政年份:2009
- 资助金额:
$ 30.78万 - 项目类别:
Cell cycle regulation by protein phosphatase 2A
蛋白磷酸酶 2A 的细胞周期调节
- 批准号:
8204969 - 财政年份:2009
- 资助金额:
$ 30.78万 - 项目类别:
PROTEIN PHOSPHATASES--1996 FASEB CONFERENCE
蛋白质磷酸酶--1996 FASEB 会议
- 批准号:
2115429 - 财政年份:1996
- 资助金额:
$ 30.78万 - 项目类别:
相似国自然基金
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向免疫疗法标志物识别的基于多特征融合的肽与MHC亲和力预测研究
- 批准号:62302277
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向多场景应用的药物-靶标结合亲和力预测研究
- 批准号:62371403
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
NOS3 and p38 MAP kinase - is the interaction between them a mechanism of p38 regulation?
NOS3 和 p38 MAP 激酶 - 它们之间的相互作用是 p38 调节机制吗?
- 批准号:
10653595 - 财政年份:2023
- 资助金额:
$ 30.78万 - 项目类别:
Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention
开发用于治疗和预防动脉粥样硬化的 Fortilin 小分子抑制剂
- 批准号:
10706870 - 财政年份:2023
- 资助金额:
$ 30.78万 - 项目类别:
CD37 as a Regulator of Platelet Patho(Physiological) Responses
CD37 作为血小板病理(生理)反应的调节剂
- 批准号:
10638254 - 财政年份:2023
- 资助金额:
$ 30.78万 - 项目类别:
Mechanistic Studies of the Novel Human Coronary Artery Disease Gene SVEP1
人类新型冠状动脉疾病基因SVEP1的机制研究
- 批准号:
10590681 - 财政年份:2022
- 资助金额:
$ 30.78万 - 项目类别:
Mechanisms of Mechanotransduction by LIM Domain Proteins
LIM 结构域蛋白的力转导机制
- 批准号:
10657771 - 财政年份:2022
- 资助金额:
$ 30.78万 - 项目类别: